Archive · 4 Sep 2026
Broker Recommends Buy on Emcure Pharma, Sets ₹2,305 Target
A broker that studies companies thinks Emcure Pharmaceuticals could perform well.
It has recommended buying the company’s shares.
The broker set a future price target of ₹2,305 per share.
The shares were priced at ₹1,932.80 when the report was prepared.
Emcure sells medicines in India and other countries.
It has businesses in areas such as women’s healthcare, injectable medicines and chronic treatments.
The company also works with global innovators to bring established medicines to markets.
New opportunities include GLP-1 medicines, eye care, skin care and consumer health.
The broker believes Emcure’s varied businesses can support growth.
Its valuation uses an estimated FY28 earnings figure of ₹76.8 per share.
A broker has issued a Buy recommendation on Emcure Pharmaceuticals with a target price of ₹2,305 per share.
Emcure’s current market price was reported at ₹1,932.80, implying potential upside to the target.
The Pune-headquartered company operates across domestic and international pharmaceutical markets.
Growth opportunities include GLP-1 treatments, MASH, ophthalmics, dermatology, consumer health and complex generics.
The valuation is based on 30 times estimated FY28 earnings per share of ₹76.8.
- Who
- Emcure Pharmaceuticals and the broker issuing the recommendation.
- What
- A Buy recommendation and a ₹2,305 target price for Emcure Pharmaceuticals shares.
- When
- Published September 4, 2026.
- Where
- Emcure is headquartered in Pune, India, and operates in domestic and international markets.
- Why
- The broker expects growth from diversified pharmaceutical businesses, international platforms, strategic partnerships and complex-product opportunities.
- Recommendation
- Buy
- Target price
- ₹2,305 per share
- Reported market price
- ₹1,932.80 per share
- Valuation basis
- 30 times estimated FY28 earnings per share
- Estimated FY28 EPS
- ₹76.8
- Headquarters
- Pune, India
- Key opportunities
- GLP-1, MASH, ophthalmics, dermatology, consumer health and complex generics